Evidence map›Paper›PMID 34718916›Full record

ArticleAnnals of surgical oncology2022

Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?

W Hugo van Joolingen, Marnix J A Rasing, Max Peters, Anne S R van Lindert, Linda M de Heer, Mieke J Aarts, Joost J C Verhoeff, Peter S N van Rossum

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

W Hugo van JoolingenDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Marnix J A RasingDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Max PetersDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Anne S R van LindertDepartment of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands.
Linda M de HeerDepartment of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Mieke J AartsNetherlands Cancer Registry, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
Joost J C VerhoeffDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. J.J.C.Verhoeff-10@umcutrecht.nl.
Peter S N van RossumDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. P.S.N.vanRossum-2@umcutrecht.nl.
University Medical Center Utrecht · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIrradical resection of non-small-cell lung cancer (NSCLC) is a detrimental prognostic factor. Recently, Rasing et al. presented an internationally validated risk score for pre-treatment prediction of irradical resection. We hypothesized that chemoradiation therapy (CRT) could serve as an alternative approach in patients with a high risk score and compared overall survival (OS) outcomes between surgery and CRT.

methodsPatients from a population-based cohort with stage IIB-III NSCLC between 2015 and 2018 in The Netherlands were selected. Patients with a 'Rasing score' > 4 who underwent surgery were matched with patients who underwent CRT using 1:1 nearest-neighbor propensity score matching. The primary endpoint of OS was compared using a Kaplan-Meier analysis.

resultsIn total, 2582 CRT and 638 surgery patients were eligible. After matching, 523 well-balanced pairs remained. Median OS in the CRT group was 27.5 months, compared with 45.6 months in the surgery group (HR 1.44, 95% CI 1.23-1.70, p < 0.001). The 114 surgical patients who underwent an R1-2 resection (21.8%) had a worse median OS than the CRT group (20.2 versus 27.5 months, HR 0.77, 95% CI 0.61-0.99, p = 0.039).

conclusionIn NSCLC patients at high predicted risk of irradical resection, CRT appears to yield inferior survival compared with surgery. Therefore, choosing CRT instead of surgery cannot solely be based on the Rasing score. Since patients receiving an R1-2 resection do have detrimental outcomes compared with primary CRT, the treatment decision should be based on additional information, such as imaging features, comorbidities, patient preference, and the surgeon's confidence in achieving an R0 resection.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyHumansKaplan-Meier EstimatePropensity ScoreRetrospective StudiesTreatment Outcome

Identifiers

PMID34718916
PMCPMC8810471
OpenAlexW3210244054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.